Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma

Background The role of nucleos(t)ide analogs (NAs) therapy in intermediate and advanced hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains unclear. Aims The aim was to evaluate the effect of NAs therapy on survival of intermediate- and advanced-stage HBV-related HCC patients init...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2019-08, Vol.64 (8), p.2187-2198
Main Authors: Jian, Zhi-Wei, Wu, Xi-Wen, Chen, Zhen-Xin, Wang, Jun-Cheng, Peng, Jing-Yuan, Lao, Xiang-Ming
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Biochemistry
Biomarkers, Tumor - blood
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - virology
Chemoembolization
Chemoembolization, Therapeutic
Combined Modality Therapy
Female
Gastroenterology
Hepatitis
Hepatitis B
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - drug therapy
Hepatology
Humans
Liver cancer
Liver Function Tests
Liver Neoplasms - drug therapy
Liver Neoplasms - virology
Male
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Staging
Nucleosides - analogs & derivatives
Nucleosides - therapeutic use
Oncology
Original Article
Propensity Score
Retrospective Studies
Survival Rate
Transplant Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The role of nucleos(t)ide analogs (NAs) therapy in intermediate and advanced hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains unclear. Aims The aim was to evaluate the effect of NAs therapy on survival of intermediate- and advanced-stage HBV-related HCC patients initially treated with chemoembolization. Methods A total of 1016 Barcelona Clinic Liver Cancer (BCLC) stage B/C HBV-related HCC patients initially treated with chemoembolization were included. Propensity score matching (PSM) was performed to decrease heterogeneity between the antiviral and non-antiviral groups. Kaplan–Meier and Cox regression analysis were performed to evaluate the effects of NAs therapy on overall survival (OS). Results Antiviral group ( n  = 394) significantly prolonged OS compared with non-antiviral group ( n  = 622) ( p  = 0.003). NAs therapy ( p 
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-019-05543-4